Relmada Therapeutics, Inc.
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Sergio Traversa
- Full Time Employees
- 17
- Sector
- Health technology
- Industry
- Pharmaceuticals: major
- Address
- 2222 Ponce de Leon Blvd. Coral Gables FL United States 33134
- IPO Date
- Mar 3, 2014
- CIK
- 0001553643
- Website
- relmada.com
- Similar Companies
- Business
- Relmada Therapeutics, Inc. (Nasdaq: RLMD) is a clinical-stage biotechnology company that develops novel treatments targeting central nervous system disorders and oncology. The company offers NDV-01, a controlled-release intravesical formulation of gemcitabine and docetaxel in Phase 2 clinical trials for non-muscle invasive bladder cancer; sepranolone, a neurosteroid epimer of allopregnanolone that is Phase 2b-ready for Prader-Willi Syndrome and other compulsivity-related disorders including Tourette Syndrome and excessive tremor; and is advancing programs in neurodegenerative diseases based on psilocybin derivatives. Relmada Therapeutics focuses on patient populations with unmet needs in CNS diseases such as major depressive disorder and metabolic conditions, as well as aggressive bladder cancer; it operates primarily in the United States. Founded in 2004, the company is headquartered in Coral Gables, Florida. In recent developments, Relmada discontinued its REL-1017 program for major depressive disorder in July 2025 following disappointing Phase 3 trial results; acquired NDV-01 and sepranolone to reprioritize its pipeline; priced a $100 million underwritten common stock offering in November 2025 with participation from investors including Janus Henderson Investors and OrbiMed to fund clinical advancement and general corporate purposes; and reported positive 9-month follow-up data for NDV-01 showing a 92% overall response rate alongside reduced operating expenses in its Q3 2025 financial results.
Company News
Relmada Therapeutics, Inc. (NASDAQ:RLMD) Stock Has Consensus Target Price of $12.00
812,059 Shares in Relmada Therapeutics, Inc. $RLMD Purchased by Bank of America Corp DE
5 Small Drug Stocks Poised to Benefit From a Biotech Recovery
Relmada Therapeutics to Participate at the Wells Fargo 21st Annual Healthcare Conference
After Plunging 18.5% in 4 Weeks, Here's Why the Trend Might Reverse for Relmada Therapeutics (RLMD)
Here's Why Relmada Therapeutics (RLMD) Is a Great 'Buy the Bottom' Stock Now
Down 29.6% in 4 Weeks, Here's Why Relmada Therapeutics (RLMD) Looks Ripe for a Turnaround
Relmada Therapeutics Q2 Earnings Call Highlights
Relmada Therapeutics, Inc. (RLMD) Q2 2026 Earnings Call Transcript
Critical Review: Relmada Therapeutics (NASDAQ:RLMD) versus Novo Nordisk A/S (NYSE:NVO)
ADAR1 Capital Management LLC Grows Stock Position in Relmada Therapeutics, Inc. $RLMD
Relmada Therapeutics Appoints Uro-Oncology Leader Bipin Dalmia as Chief Business Officer
Relmada Therapeutics, Inc. (NASDAQ:RLMD) Sees Significant Growth in Short Interest
Relmada Therapeutics to Report Second Quarter 2026 Financial Results on Thursday, August 6, 2026
Relmada Therapeutics Joins Russell 2000® and Russell 3000® Indexes
Relmada's Cancer Drug Candidate Sparks Fresh Bullish Call
Relmada Therapeutics Appoints CNS Drug Development Veteran Michael Quirk as Senior Advisor for Sepranolone Program
Relmada Therapeutics to Present at the Jefferies Global Healthcare Conference
Relmada Therapeutics Q1 Earnings Call Highlights
Relmada Therapeutics, Inc. (RLMD) Q1 2026 Earnings Call Transcript